The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| 2SEVENTY BIO INC | COMMON STOCK | 901384107 | 24,036 | 1,408,901 | SH | SOLE | 1,408,901 | 0 | 0 | ||
| ADAGIO THERAPEUTICS INC | COM | 00534A102 | 8,834 | 1,937,207 | SH | SOLE | 1,937,207 | 0 | 0 | ||
| AEGLEA BIOTHERAPEUTICS INC | COM | 00773J103 | 6,550 | 2,847,689 | SH | SOLE | 2,847,689 | 0 | 0 | ||
| AMYLYX PHARMACEUTICALS INC | COM | 03237H101 | 35,415 | 2,756,050 | SH | SOLE | 2,756,050 | 0 | 0 | ||
| ANNEXON INC | COM | 03589W102 | 8,850 | 3,241,628 | SH | SOLE | 3,241,628 | 0 | 0 | ||
| APTINYX INC | COM | 03836N103 | 20,184 | 8,891,758 | SH | SOLE | 8,891,758 | 0 | 0 | ||
| ARCUTIS BIOTHERAPEUTICS INC | COM | 03969K108 | 76,641 | 3,979,292 | SH | SOLE | 3,979,292 | 0 | 0 | ||
| ARYA SCIENCES ACQU CORP IV | CL A | G31659108 | 6,860 | 700,000 | SH | SOLE | 700,000 | 0 | 0 | ||
| ARYA SCIENCES ACQUISITN CORP | CLASS A ORD SHS | G31658100 | 4,855 | 500,000 | SH | SOLE | 500,000 | 0 | 0 | ||
| ATEA PHARMACEUTICALS INC | COM | 04683R106 | 17,946 | 2,485,638 | SH | SOLE | 2,485,638 | 0 | 0 | ||
| BCLS ACQUISITION CORP | COM CL A | G0904B105 | 4,812 | 487,500 | SH | SOLE | 487,500 | 0 | 0 | ||
| C4 THERAPEUTICS INC | COM STK | 12529R107 | 39,840 | 1,642,210 | SH | SOLE | 1,642,210 | 0 | 0 | ||
| CRINETICS PHARMACEUTICALS IN | COM | 22663K107 | 44,552 | 2,029,701 | SH | SOLE | 2,029,701 | 0 | 0 | ||
| DYNAVAX TECHNOLOGIES CORP | COM NEW | 268158201 | 91,219 | 8,415,000 | SH | SOLE | 8,415,000 | 0 | 0 | ||
| EQRX INC | COM | 26886C107 | 41,315 | 10,003,573 | SH | SOLE | 10,003,573 | 0 | 0 | ||
| FRAZIER LIFESCIENCES ACQU CO | UNIT 12/09/2025 | G3710A121 | 2,997 | 300,000 | SH | SOLE | 300,000 | 0 | 0 | ||
| JIYA ACQUISITION CORP | COM CL A | 47760M102 | 2,949 | 300,000 | SH | SOLE | 300,000 | 0 | 0 | ||
| MARINUS PHARMACEUTICALS INC | COM NEW | 56854Q200 | 13,380 | 1,431,058 | SH | SOLE | 1,431,058 | 0 | 0 | ||
| MERSANA THERAPEUTICS INC | COM | 59045L106 | 26,023 | 6,522,030 | SH | SOLE | 6,522,030 | 0 | 0 | ||
| NAUTILUS BIOTECHNOLOGY INC | COM | 63909J108 | 8,680 | 2,000,000 | SH | SOLE | 2,000,000 | 0 | 0 | ||
| NURIX THERAPEUTICS INC | COM | 67080M103 | 17,993 | 1,284,313 | SH | SOLE | 1,284,313 | 0 | 0 | ||
| NUVALENT INC | COM | 670703107 | 47,615 | 3,428,014 | SH | SOLE | 3,428,014 | 0 | 0 | ||
| OMEGA ALPHA SPAC | CL A | G6749V107 | 3,928 | 400,000 | SH | SOLE | 400,000 | 0 | 0 | ||
| PANACEA ACQUISITION CORP II | CL A SHS | G6882C106 | 4,875 | 500,000 | SH | SOLE | 500,000 | 0 | 0 | ||
| PHARVARIS N V | COM | N69605108 | 57,680 | 3,180,601 | SH | SOLE | 3,180,601 | 0 | 0 | ||
| RAPID MICRO BIOSYSTEMS INC | CLASS A COM | 75340L104 | 57,271 | 8,434,560 | SH | SOLE | 8,434,560 | 0 | 0 | ||
| RESEARCH ALLIANCE CORP II | COM CL A | 760873109 | 9,760 | 1,000,000 | SH | SOLE | 1,000,000 | 0 | 0 | ||
| SAVARA INC | COM | 805111101 | 15,226 | 11,622,598 | SH | SOLE | 11,622,598 | 0 | 0 | ||
| SOLID BIOSCIENCES INC | COM | 83422E105 | 9,516 | 7,929,918 | SH | SOLE | 7,929,918 | 0 | 0 | ||
| SPRINGWORKS THERAPEUTICS INC | COM | 85205L107 | 272,679 | 4,831,307 | SH | SOLE | 4,831,307 | 0 | 0 | ||
| SYROS PHARMACEUTICALS INC | COM | 87184Q107 | 7,455 | 6,264,420 | SH | SOLE | 6,264,420 | 0 | 0 | ||
| TANGO THERAPEUTICS INC | COM | 87583X109 | 14,567 | 1,921,790 | SH | SOLE | 1,921,790 | 0 | 0 | ||
| X4 PHARMACEUTICALS INC | COM | 98420X103 | 5,284 | 3,019,540 | SH | SOLE | 3,019,540 | 0 | 0 | ||
| XILIO THERAPEUTICS INC | COM | 98422T100 | 19,834 | 2,805,413 | SH | SOLE | 2,805,413 | 0 | 0 | ||